These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38037229)
1. Pathologic Complete Response After Gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced Gastric Cancer: A Case Report. Lin Y; Chen Y; Lin S; Zheng J; Zhang X; Gan L J Immunother; 2024 Apr; 47(3):101-105. PubMed ID: 38037229 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort. Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P Front Immunol; 2023; 14():1122121. PubMed ID: 37215127 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study. Wang X; Huang J; Huang H; Liu Y; Ji C; Liu J Invest New Drugs; 2023 Aug; 41(4):579-586. PubMed ID: 37368088 [TBL] [Abstract][Full Text] [Related]
4. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy]. Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004 [No Abstract] [Full Text] [Related]
5. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study. Xu C; Xie X; Kang N; Jiang H J Cancer Res Clin Oncol; 2023 Jul; 149(7):4091-4099. PubMed ID: 36042044 [TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer. Yang J; Li J; Deng Q; Chen Z; He K; Chen Y; Fu Z BMC Cancer; 2023 Mar; 23(1):246. PubMed ID: 36918834 [TBL] [Abstract][Full Text] [Related]
7. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors]. Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301 [No Abstract] [Full Text] [Related]
8. [Neoadjuvant treatment for locally advanced gastric cancer]. Zhao LL; Zhao DB; Chen YT Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):907-911. PubMed ID: 33256300 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540 [TBL] [Abstract][Full Text] [Related]
10. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study. He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L Front Immunol; 2022; 13():853922. PubMed ID: 35720312 [TBL] [Abstract][Full Text] [Related]
11. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021 [TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer]. Zhu ZG Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1331-1336. PubMed ID: 38644278 [TBL] [Abstract][Full Text] [Related]
13. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma. Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673 [TBL] [Abstract][Full Text] [Related]
14. Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review. Cui G; Qu D; Bai Y; Sun X; Li Y; Yang Y Oncol Lett; 2023 Sep; 26(3):388. PubMed ID: 37559583 [TBL] [Abstract][Full Text] [Related]
15. Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report. Zhu Z; Dai PL; Han S; Qiu E; Wang Y; Li Z Front Oncol; 2023; 13():1147636. PubMed ID: 37234987 [TBL] [Abstract][Full Text] [Related]
16. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591 [TBL] [Abstract][Full Text] [Related]
17. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858 [TBL] [Abstract][Full Text] [Related]
18. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556 [TBL] [Abstract][Full Text] [Related]
20. [Significance and treatment strategies of pathologic complete response after neoadjuvant therapy for gastric cancer]. Chen J; Liu FL Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul; 27(7):666-671. PubMed ID: 39004981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]